查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
克隆和诱变市场规模,份额和趋势分析报告:按产品(克隆试剂盒,诱变试剂盒),按技术(Topo PCR克隆,平端克隆),按最终用途,按地区,分部预测,2023-2030年
市场调查报告书
商品编码
1178548

克隆和诱变市场规模,份额和趋势分析报告:按产品(克隆试剂盒,诱变试剂盒),按技术(Topo PCR克隆,平端克隆),按最终用途,按地区,分部预测,2023-2030年

Cloning And Mutagenesis Market Size, Share & Trends Analysis Report By Product (Cloning Kits, Mutagenesis Kits), By Technology (Topo PCR Cloning, Blunt End Cloning), By End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

克隆和诱变市场的增长和趋势

Grand View Research, Inc. 的一份新报告预测，2023 年至 2030 年全球克隆和诱变市场将以 18.97% 的复合年增长率增长，到 2030 年将达到 94.4 亿美元。对用于药物开发的蛋白质工程的日益关注以及对基因工程产品不断增长的需求是推动市场的主要因素。此外，遗传病和慢性病的增加增加了对个性化医疗的需求。

克隆和诱变是药物开发中蛋白质工程中使用的基本技术。这些技术帮助研究人员通过核甘酸插入、删除和替换来改变蛋白质序列，以开发治疗性蛋白质。此外，克隆和诱变可以帮助开发更有效、更安全、成本更低且更容易获得的药物。例如，目前有超过200种多□和蛋白质药物获得FDA批准。因此，这些技术在蛋白质工程中的应用可能会在预测期内推动市场增长。

预计 COVID-19 大流行将对市场增长产生积极影响。克隆和诱变技术已被用于克隆 SARS-CoV-2 基因组。例如，在 2020 年 5 月发表在《Nature》杂誌上的一篇论文中，研究人员使用基于酵母的方法克隆了 SARC-CoV-2 基因组。基因组修饰和重建对于研究感染和復制方法以及可能对病毒起作用的药物和疫苗至关重要。因此，COVID-19 相关研究有望提高这些技术的利用率，从而推动预测期内的市场增长。

遗传病和慢性病的日益流行增加了对个性化医疗的需求。克隆和诱变技术用于研究个体的特定疾病，以帮助诊断、规划治疗和确认治疗效果。此外，增加对个性化医疗的资助有望在研究期间促进克隆和诱变的应用。例如，2022 年 2 月，VariantyxS 获得了价值 4150 万美元的资金，用于推出一种新的精准肿瘤学解决方案。

此外，在合成生物学中越来越多地使用克隆和诱变工具推动了市场增长。合成生物学使用克隆和诱变来帮助微调药物，方法是改善现有药物的治疗特性并最大限度地减少或消除对个体的副作用。合成基因为专门的肿瘤学组织开闢了道路，可以开发针对患者肿瘤特定 DNA 序列的个性化癌症疫苗。几种这样的个性化癌症疫苗正处于临床阶段。还有几种基于基因的疫苗正在开发中以对抗 COVID-19，但需要克隆和诱变技术来生产具有成本效益和高效的疫苗。预计此类应用将在研究期间推动市场增长。

另一方面，高昂的维护成本、合格研究人员的有限生存能力以及与克隆和诱变生成工具相关的高培训要求可能会在一定程度上限制市场增长。然而，主要参与者正在不断努力开发具有成本效益的设备，并提供一些实践培训计划来克服限制，这有望推动市场增长。可能会创造前景。

克隆和诱变市场报告要点

按产品划分，克隆试剂盒部分在 2022 年占据了最大份额。这是由于这些试剂盒的广泛应用，包括生物製药、基因治疗和基因分析。

从技术上看，TOPO PCR 克隆部分在 2022 年占据了最大份额。这是由于与连接、无限克隆和简单引物设计等技术相关的优势。

按最终用途划分，生物製药和製药公司在 2022 年占据最大份额，原因是克隆和诱变技术广泛用于药物发现和药物开发。

由于政府投资举措的增加、癌症等慢性病发病率的增加以及对生物技术技术的高需求，北美将在 2022 年主导全球市场

由于政府增加研发投资、对新疗法的需求增加以及经济改善，预计亚太地区未来将出现显着增长。

目录

第一章研究方法论

  • 市场细分和范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查详情
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法一：商品流动方法
      • 方法 2：使用自下而上的方法进行国别市场估算
  • 全球市场：复合年增长率计算
  • 调查假设
  • 二级信息列表
  • 主要信息列表
  • 目的
  • 缩略语表

第二章市场定义

第三章执行摘要

  • 市场概况

4. 全球克隆和诱变市场变量、趋势和范围

  • 克隆和诱变市场谱系展望
    • 母公司市场展望
  • 绘製渗透率和增长前景
  • 监管框架
  • 市场驱动力分析
    • 对个性化医疗的需求不断增长
    • 对蛋白质工程的兴趣日益浓厚
    • 对转基因产品的需求不断增长
  • 市场约束因素分析
    • 与克隆和诱变工具和设备相关的高维护成本
    • 合格研究人员的可用性有限，需要进行有关克隆和诱变过程的高级培训
  • 市场机会分析
    • 增加克隆和诱变在合成生物学中的应用
  • 波特五力分析
  • 克隆诱变市场：COVID-19 的影响分析

5. 克隆和诱变市场：细分分析，按产品，2018-2030 年（百万美元）

  • 全球克隆和诱变市场：产品变异分析
  • 克隆试剂盒
  • 诱变试剂盒
  • 其他

6. 克隆和诱变市场：细分分析，按技术，2018-2030 年（百万美元）

  • 全球克隆和诱变市场：技术波动分析
  • 拓扑聚合□链反应克隆
  • 平端克隆
  • 无缝克隆
  • 定点诱变
  • 其他

7. 克隆和诱变市场：细分分析，按最终用途，2018-2030 年（百万美元）

  • 克隆和诱变市场：最终用户变异分析
  • 生物製药和製药公司
  • CRO 和 CMO
  • 学术/研究机构

8. 克隆和诱变市场：-2018-2030 年按地区细分分析（百万美元）

  • 克隆和诱变市场：区域差异分析
  • 北美
    • SWOT分析
    • 美国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 加拿大
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
  • 欧洲
    • SWOT分析
    • 德国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 英国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 法国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 意大利
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 西班牙
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 丹麦
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 瑞典
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 挪威
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
  • 亚太地区
    • SWOT分析
    • 日本
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 中国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 印度
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 韩国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 澳大利亚
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 泰国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
  • 拉丁美洲
    • SWOT分析
    • 巴西
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 墨西哥
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 阿根廷
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
  • 多边环境协定
    • SWOT分析
    • 南非
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 沙特阿拉伯
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 阿拉伯联合酋长国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 科威特
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景

第九章竞争格局

  • 参会概况
    • Agilent Technologies, Inc.
    • Takara Bio Co., Ltd.
    • Thermo Fisher Scientific
    • new england bio lab
    • Merck KGaA
    • Promega Corporation
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • Jena Bioscience GmbH
    • assay jenny
    • Trans Gen Biotech Co., Ltd.
  • 财务绩效
  • 进入公司
    • 市场领导者
      • 2022 年克隆和诱变市场份额分析
    • 战略规划
      • 扩张
      • 获得
      • 合作
      • 产品/服务发布
      • 合伙
      • 其他
Product Code: GVR-4-68040-010-3

Cloning And Mutagenesis Market Growth & Trends:

The global cloning and mutagenesis market size is expected to reach USD 9.44 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 18.97% from 2023 to 2030. Growing focus on protein engineering for drug development and increasing demand for genetically modified products are major factors driving the market. In addition, the rising prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine.

Cloning and mutagenesis are the basic methodologies employed in protein engineering during drug development. These techniques help researchers in the modification of protein sequences through insertion, deletion, or substitution of nucleotides to develop therapeutic proteins. In addition, cloning and mutagenesis aid in the development of more efficient and safer drugs, which can be readily available at a lower cost. For instance, currently, there are more than 200 peptide and protein drugs approved by the FDA. Hence, applications of these techniques in protein engineering are likely to fuel market growth over the forecast years.

The COVID-19 pandemic is expected to positively influence market growth. Cloning and mutagenesis techniques are used to clone the SARS-CoV-2 genome. For instance, according to an article published in Nature in May 2020, researchers have constructed a clone of the SARC-CoV-2 genome by using yeast-based method. Modifying or reconstructing genomes is essential for studying methods of infection, replication, and potential drugs and vaccines that might work against the virus. As a result, the usage of these techniques has increased due to COVID-19-related research, which is expected to fuel the market growth during the forecast period.

The growing prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine. Cloning and mutagenesis techniques are used in studying a particular disease of an individual to aid diagnosis, develop a treatment plan, and identify the treatment effect. Moreover, increasing funding for personalized medicine is anticipated to boost the applications of cloning and mutagenesis during the study period. For instance, in February 2022, VariantyxS secured funding worth USD 41.5 million to launch novel solutions in precision oncology.

Furthermore, increasing applications of cloning and mutagenesis tools in synthetic biology are accelerating market growth. Synthetic biology is aiding in fine-tuning of already available drugs by using cloning and mutagenesis to improve their therapeutic attributes and produce minimal or no side effects for individuals. Synthetic genes created the way for oncology-focused organizations to develop personalized cancer vaccines to the specific DNA sequence of a patient's tumor. Several such personalized cancer vaccines are in the clinical phase. There are several gene-based vaccines that are also in development to fight COVID-19, which require cloning and mutagenesis techniques to produce cost-effective and efficient vaccines. Such applications are expected to fuel the market growth during the study period.

On the other hand, high maintenance cost associated with cloning and mutagenesis tools, limited viability of qualified researchers. and the need for advanced training may limit the market growth to a certain extent. However, key players are continuously striving to develop cost-effective instruments and offering several hands-on training programs to overcome the limitations, which is likely to create growth prospects for the market.

Cloning And Mutagenesis Market Report Highlights:

  • By product, the cloning kits segment held the largest share in 2022. This is attributed to the broad range of applications of these kits in biopharmaceuticals, gene therapy, and gene analysis among others
  • By technology, the TOPO PCR cloning segment held the largest share in 2022 due to the advantages associated with the technology such as ligation and restriction-free cloning and simple design of primers
  • By end-user, the biopharmaceutical and pharmaceutical companies segment held the largest share in 2022 owing to the widespread use of cloning and mutagenesis in biopharmaceuticals for drug discovery and development
  • North America dominated the global market in 2022 due to a rise in investment initiatives by the government, increasing incidence of chronic diseases such as cancer, and high demand for biotechnology techniques
  • Asia Pacific is expected to grow considerably in the future owing to the increasing R&D investment by governments, rising demand for novel therapeutics, and improving economy

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity flow approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

  • 3.1 Market Summary

Chapter 4 Global Cloning and Mutagenesis Market Variables, Trends, & Scope

  • 4.1 Cloning and Mutagenesis Market Lineage Outlook
    • 4.1.1 Parent market outlook
  • 4.2 Penetration and Growth Prospect Mapping
  • 4.3 Regulatory Framework
  • 4.4 Market Driver Analysis
    • 4.4.1 Increasing demand for personalized medicine
    • 4.4.2 Growing focus on protein engineering
    • 4.4.3 Rising demand for genetically modified products
  • 4.5 Market Restraint Analysis
    • 4.5.1 High maintanance cost associated with cloning and mutagenesis tools & instruments
    • 4.5.2 Limited aviability of qualified researchers and need for advanced training in cloning and mutagenesis processes
  • 4.6 Market Opportunity Analysis
    • 4.6.1 Increasing applications of cloning and mutagenesis in synthetic biology
  • 4.7 Porter's Five Forces Analysis
  • 4.8 Cloning and Mutagenesis Market: Covid-19 Impact Analysis

Chapter 5 Cloning and Mutagenesis Market - Segment Analysis, by product, 2018 - 2030 (USD Million)

  • 5.1 Global Cloning and Mutagenesis Market: Product Movement Analysis
  • 5.2 Cloning Kits
    • 5.2.1 Cloning kits market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Mutagenesis Kits
    • 5.3.1 Mutagenesis kits market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4 Others
    • 5.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Cloning and Mutagenesis Market - Segment Analysis, by Technology, 2018 - 2030 (USD Million)

  • 6.1 Global Cloning and Mutagenesis Market: Technology Movement Analysis
  • 6.2 Topo PCR Cloning
    • 6.2.1 Topo PCR cloning market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Blunt End Cloning
      • 6.3.1Blunt end cloning market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Seamless Cloning
    • 6.4.1 Seamless cloning market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5 Site-Directed Mutagenesis
    • 6.5.1 Site-directed mutagenesis market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6 Others
    • 6.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Cloning and Mutagenesis Market - Segment Analysis, by End-user, 2018 - 2030 (USD Million)

  • 7.1 Cloning and Mutagenesis Market: End-user Movement Analysis
  • 7.2 Biopharmaceutical & Pharmaceutical Companies
    • 7.2.1 Biopharmaceutical & pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3 CROs & CMOs
    • 7.3.1 CROs & CMOs market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4. Academic & Research Institutes
    • 7.4.1 Academic & research institutes market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Cloning and Mutagenesis Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 8.1 Cloning and Mutagenesis Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 SWOT Analysis
      • 8.2.1.1 North America cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.2.1.2 North America cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.2.1.3 North America cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 Key Country Dynamics
      • 8.2.2.2 Target Disease Prevalence
      • 8.2.2.3 Competitive Scenario
      • 8.2.2.4 Regulatory Framework
      • 8.2.2.5 Reimbursement Scenario
      • 8.2.2.6 U.S. cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.2.2.7 U.S. cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.2.2.8 U.S. cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Key Country Dynamics
      • 8.2.3.2 Target Disease Prevalence
      • 8.2.3.3 Competitive Scenario
      • 8.2.3.4 Regulatory Framework
      • 8.2.3.5 Reimbursement Scenario
      • 8.2.3.6 Canada cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.2.3.7 Canada cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.2.3.8 Canada cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 SWOT Analysis
      • 8.3.1.1 Europe cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.1.2 Europe cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.1.4 Europe cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.2 Germany
      • 8.3.2.1 Key Country Dynamics
      • 8.3.2.2 Target Disease Prevalence
      • 8.3.2.3 Competitive Scenario
      • 8.3.2.4 Regulatory Framework
      • 8.3.2.5 Reimbursement Scenario
      • 8.3.2.6 Germany cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.2.7 Germany cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.2.8 Germany cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.3 U.K.
      • 8.3.3.1 Key Country Dynamics
      • 8.3.3.2 Target Disease Prevalence
      • 8.3.3.3 Competitive Scenario
      • 8.3.3.4 Regulatory Framework
      • 8.3.3.5 Reimbursement Scenario
      • 8.3.3.6 U.K. cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.3.7 U.K. cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.3.8 U.K. cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.4 France
      • 8.3.4.1 Key Country Dynamics
      • 8.3.4.2 Target Disease Prevalence
      • 8.3.4.3 Competitive Scenario
      • 8.3.4.4 Regulatory Framework
      • 8.3.4.5 Reimbursement Scenario
      • 8.3.4.6 France cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.4.7 France cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.4.8 France cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.5 Italy
      • 8.3.5.1 Key Country Dynamics
      • 8.3.5.2 Target Disease Prevalence
      • 8.3.5.3 Competitive Scenario
      • 8.3.5.4 Regulatory Framework
      • 8.3.5.5 Reimbursement Scenario
      • 8.3.5.6 Italy cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.5.7 Italy cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.5.8 Italy cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.6 Spain
      • 8.3.6.1 Key Country Dynamics
      • 8.3.6.2 Target Disease Prevalence
      • 8.3.6.3 Competitive Scenario
      • 8.3.6.4 Regulatory Framework
      • 8.3.6.5 Reimbursement Scenario
      • 8.3.6.6 Spain cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.6.7 Spain cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.6.8 Spain cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.7 Denmark
      • 8.3.7.1 Key Country Dynamics
      • 8.3.7.2 Target Disease Prevalence
      • 8.3.7.3 Competitive Scenario
      • 8.3.7.4 Regulatory Framework
      • 8.3.7.5 Reimbursement Scenario
      • 8.3.7.6 Denmark cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.7.7 Denmark cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.7.8 Denmark cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.8 Sweden
      • 8.3.8.1 Key Country Dynamics
      • 8.3.8.2 Target Disease Prevalence
      • 8.3.8.3 Competitive Scenario
      • 8.3.8.4 Regulatory Framework
      • 8.3.8.5 Reimbursement Scenario
      • 8.3.8.6 Sweden cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.8.7 Sweden cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.8.8 Sweden cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.9 Norway
      • 8.3.9.1 Key Country Dynamics
      • 8.3.9.2 Target Disease Prevalence
      • 8.3.9.3 Competitive Scenario
      • 8.3.9.4 Regulatory Framework
      • 8.3.9.5 Reimbursement Scenario
      • 8.3.9.6 Norway cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.9.7 Norway cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.9.8 Norway cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 SWOT Analysis
      • 8.4.1.1 Asia Pacific cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.1.2 Asia Pacific cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.1.3 Asia Pacific cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Key Country Dynamics
      • 8.4.2.2 Target Disease Prevalence
      • 8.4.2.3 Competitive Scenario
      • 8.4.2.4 Regulatory Framework
      • 8.4.2.5 Reimbursement Scenario
      • 8.4.2.6 Japan cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.2.7 Japan cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.2.8 Japan cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 Key Country Dynamics
      • 8.4.3.2 Target Disease Prevalence
      • 8.4.3.3 Competitive Scenario
      • 8.4.3.4 Regulatory Framework
      • 8.4.3.5 Reimbursement Scenario
      • 8.4.3.6 China cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.3.7 China cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.3.8 China cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 Key Country Dynamics
      • 8.4.4.2 Target Disease Prevalence
      • 8.4.4.3 Competitive Scenario
      • 8.4.4.4 Regulatory Framework
      • 8.4.4.5 Reimbursement Scenario
      • 8.4.4.6 India cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.4.7 India cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.4.8 India cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.5 South Korea
      • 8.4.5.1 Key Country Dynamics
      • 8.4.5.2 Target Disease Prevalence
      • 8.4.5.3 Competitive Scenario
      • 8.4.5.4 Regulatory Framework
      • 8.4.5.5 Reimbursement Scenario
      • 8.4.5.6 South Korea cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.5.7 South Korea cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.5.8 South Korea cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.6 Australia
      • 8.3.9.1 Key Country Dynamics
      • 8.4.6.2 Target Disease Prevalence
      • 8.4.6.3 Competitive Scenario
      • 8.4.6.4 Regulatory Framework
      • 8.4.6.5 Reimbursement Scenario
      • 8.4.6.6 Australia cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.6.7 Australia cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.6.8 Australia cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.7 Thailand
      • 8.4.7.1 Key Country Dynamics
      • 8.4.7.2 Target Disease Prevalence
      • 8.4.7.3 Competitive Scenario
      • 8.4.7.4 Regulatory Framework
      • 8.4.7.5 Reimbursement Scenario
      • 8.4.7.6 Thailand cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.7.7 Thailand cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.7.8 Thailand cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.5 Latin America
    • 8.5.1 SWOT Analysis
      • 8.5.1.1 Latin America cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.5.1.2 Latin America cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.5.1.3 Latin America cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Key Country Dynamics
      • 8.5.2.2 Target Disease Prevalence
      • 8.5.2.3 Competitive Scenario
      • 8.5.2.4 Regulatory Framework
      • 8.5.2.5 Reimbursement Scenario
      • 8.5.2.6 Brazil cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.5.2.7 Brazil cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.5.2.8 Brazil cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Key Country Dynamics
      • 8.5.3.2 Target Disease Prevalence
      • 8.5.3.3 Competitive Scenario
      • 8.5.3.4 Regulatory Framework
      • 8.5.3.5 Reimbursement Scenario
      • 8.5.3.6 Mexico cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.5.3.7 Mexico cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.5.3.8 Mexico cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.4 Argentina
      • 8.5.4.1 Key Country Dynamics
      • 8.5.4.2 Target Disease Prevalence
      • 8.5.4.3 Competitive Scenario
      • 8.5.4.4 Regulatory Framework
      • 8.5.4.5 Reimbursement Scenario
      • 8.5.4.6 Argentina cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.5.4.7 Argentina cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.5.4.8 Argentina cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.6 MEA
    • 8.6.1 SWOT Analysis
      • 8.6.1.1 MEA cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.1.2 MEA cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.1.3 MEA cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.2 South Africa
      • 8.6.4.1 Key Country Dynamics
      • 8.6.2.2 Target Disease Prevalence
      • 8.6.2.3 Competitive Scenario
      • 8.6.2.4 Regulatory Framework
      • 8.6.2.5 Reimbursement Scenario
      • 8.6.2.6 Argentina cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.2.7 Argentina cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.2.8 Argentina cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.3 Saudi Arabia
      • 8.6.3.1 Key Country Dynamics
      • 8.6.3.2 Target Disease Prevalence
      • 8.6.3.3 Competitive Scenario
      • 8.6.3.4 Regulatory Framework
      • 8.6.3.5 Reimbursement Scenario
      • 8.6.3.6 Saudi Arabia cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.3.7 Saudi Arabia cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.3.8 Saudi Arabia cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.4 UAE
      • 8.6.4.1 Key Country Dynamics
      • 8.6.4.2 Target Disease Prevalence
      • 8.6.4.3 Competitive Scenario
      • 8.6.4.4 Regulatory Framework
      • 8.6.4.5 Reimbursement Scenario
      • 8.6.4.6 UAE cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.4.7 UAE cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.4.8 UAE cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.5 Kuwait
      • 8.6.5.1 Key Country Dynamics
      • 8.6.5.2 Target Disease Prevalence
      • 8.6.5.3 Competitive Scenario
      • 8.6.5.4 Regulatory Framework
      • 8.6.5.5 Reimbursement Scenario
      • 8.6.5.6 Kuwait cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.5.7 Kuwait cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.5.8 Kuwait cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Participant's overview
    • 9.1.1 Agilent Technologies, Inc.
    • 9.1.2 Takara Bio Inc.
    • 9.1.3 Thermo Fisher Scientific, Inc.
    • 9.1.4 New England Biolabs
    • 9.1.5 Merck KGaA
    • 9.1.6 Promega Corporation
    • 9.1.7 Bio-Rad Laboratories, Inc.
    • 9.1.8 Danaher
    • 9.1.9 Jena Bioscience GmbH
    • 9.1.10 Assay Genie
    • 9.1.11 TransGen Biotech Co., Ltd.
  • 9.2 Financial performance
  • 9.3 Participant categorization
    • 9.3.1 Market leaders
      • 9.3.1.1 Cloning & mutagenesis market share analysis, 2022
    • 9.3.2 Strategy mapping
      • 9.3.2.1 Expansion
      • 9.3.2.2 Acquisition
      • 9.3.2.3 Collaborations
      • 9.3.2.4 Product/service launch
      • 9.3.2.5 Partnerships
      • 9.3.2.6 Others

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 4. Global Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 5. Global Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 6. Global Cloning and Mutagenesis Market, by Region, 2018 - 2030 (USD Million)
  • Table 7. North America Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 8. North America Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 9. North AmericaCloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 10. North America Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 11. U.S. Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 12. U.S. Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 13. U.S. Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 14. Canada Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 15. Canada Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 16. Canada Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 17. Europe Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 18. Europe Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 19. EuropeCloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 20. Europe Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 21. U.K. Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 22. U.K. Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 23. U.K. Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 24. Germany Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 25. Germany Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 26. Germany Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 27. France Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 28. France Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 29. France Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 30. Italy Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 31. Italy Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 32. Italy Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 33. Spain Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 34. Spain Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 35. Spain Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 36. Denmark Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 37. Denmark Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 38. Denmark Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 39. Sweden Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 40. Sweden Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 41. Sweden Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 42. Norway Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 43. Norway Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 44. Norway Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 47. Asia Pacific Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 49. China Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 50. China Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 51. China Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 52. India Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 53. India Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 54. India Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 55. Japan Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 56. Japan Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 57. Japan Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 58. Thailand Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 59. Thailand Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 60. Thailand Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 61. Australia Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 62. Australia Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 63. Australia Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 64. South Korea Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 65. South Korea Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 66. South Korea Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 67. Latin America Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 68. Latin America Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 69. Latin America Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 70. Latin America Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 71. Brazil Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 72. Brazil Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 73. Brazil Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 74. Mexico Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 75. Mexico Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 76. Mexico Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 77. Argentina Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 78. Argentina Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 79. Argentina Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 84. South Africa Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 85. South Africa Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 86. South Africa Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 90. UAE Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 91. UAE Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 92. UAE Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 93. Kuwait Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 94. Kuwait Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 95. Kuwait Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Cloning and Mutagenesis, Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 16 Global Cloning and Mutagenesis Market: Product Movement Analysis
  • Fig. 17 Global Cloning and Mutagenesis Market, for Cloning Kits, 2018 - 2030 (USD Million)
  • Fig. 18 Global Cloning and Mutagenesis Market, for Mutagenesis Kits, 2018 - 2030 (USD Million)
  • Fig. 19 Global Cloning and Mutagenesis Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 20 Global Cloning and Mutagenesis Market: Technology Movement Analysis
  • Fig. 21 Global Cloning and Mutagenesis Market, for Topo PCR Cloning, 2018 - 2030 (USD Million)
  • Fig. 22 Global Cloning and Mutagenesis Market, for Blunt End Cloning, 2018 - 2030 (USD Million)
  • Fig. 23 Global Cloning and Mutagenesis Market, for Seamless Cloning, 2018 - 2030 (USD Million)
  • Fig. 24 Global Cloning and Mutagenesis Market, for Site-Directed Mutagenesis, 2018 - 2030 (USD Million)
  • Fig. 25 Global Cloning and Mutagenesis Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global Cloning and Mutagenesis Market: End-user Movement Analysis
  • Fig. 27 Global Cloning and Mutagenesis Market, for Biopharmaceutical & Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 28 Global Cloning and Mutagenesis Market, for CROs & CMOs, 2018 - 2030 (USD Million)
  • Fig. 29 Global Cloning and Mutagenesis Market, for Academic & Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 30 Regional Marketplace: Key Takeaways
  • Fig. 31 Regional Outlook, 2022 & 2030
  • Fig. 32 Global Cloning and Mutagenesis Market: Regional Movement Analysis
  • Fig. 33 North America Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 37 U.K. Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)